Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040807 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00040807: Completed Phase 2 study of Head and Neck Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00040807 is a Phase 2 study of Head and Neck Cancer that has completed, run by Eastern Cooperative Oncology Group. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040807, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of irinotecan and docetaxel in treating patients who have metastatic or locally recurrent head and neck cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG irinotecan hydrochloride
Study Locations (20)
Colorado
- Medical Center of Aurora - South Campus - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center - Colorado Springs
- Porter Adventist Hospital - Denver
- St. Joseph Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- Rocky Mountain Cancer Centers - Denver Rose - Denver
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
- Swedish Medical Center - Englewood
- Sky Ridge Medical Center - Lone Tree
- Hope Cancer Care Center at Longmont United Hospital - Longmont
- St. Mary-Corwin Regional Medical Center - Pueblo
- Rocky Mountain Cancer Centers - Thornton - Thornton
Illinois
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
California
- Stanford Cancer Center at Stanford University Medical Center - Stanford
Delaware
- CCOP - Christiana Care Health Services - Newark
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Veterans Affairs Medical Center - Atlanta (Decatur) - Decatur
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-11-19 |
| Est. Completion | 2009-05-01 |
| Phase | Phase 2 |
What the finished NCT00040807 record still lists
NCT00040807 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00040807 names 20 study sites across 7 states, led by Colorado, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT00040807 about?
NCT00040807 is a clinical study titled "Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of irinotecan and docetaxel in treating patients who have metastatic or...
What is the current status of trial NCT00040807?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-11-19. Estimated completion is 2009-05-01.
What conditions does trial NCT00040807 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT00040807?
The interventions under investigation include: docetaxel (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00040807?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00040807 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI